APA (7th ed.) Citation

C, T., H, T., M, G. d. S., RO, C., C, F., F, M., . . . B, C. (2017). Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 35(22), 2473. https://doi.org/10.1200/JCO.2017.72.6984

Chicago Style (17th ed.) Citation

C, Thieblemont, et al. "Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 35, no. 22 (2017): 2473. https://doi.org/10.1200/JCO.2017.72.6984.

MLA (9th ed.) Citation

C, Thieblemont, et al. "Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, vol. 35, no. 22, 2017, p. 2473, https://doi.org/10.1200/JCO.2017.72.6984.